Raft Pharmaceuticals LLC
San Diego, CA
- UEI
- KD1LJTFV7DN8
- CAGE
- 86ZN3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 6725 Mesa Ridge Rd #260, San Diego, CA 92121, USA
- Website
- raftpharma.com
- Founded
- 2018
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of California, San Diego | UG3NS129684 | $121,803 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Regulonix LLC | Gainesville, FL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Proneurogen Inc. | Tucson, AZ | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Larix Bioscience LLC | Sunnyvale, CA | — |
| Thetis Pharmaceuticals LLC | Deep River, CT | — |
| Afasci, Inc. | Burlingame, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Raft Pharmaceuticals LLC is a biopharmaceutical company that develops novel therapies targeting lipid rafts in inflamed and activated cells, with a focus on chronic pain states. Through federal grants, Raft Pharmaceuticals provides research and development services related to drug candidates for postoperative pain, chemotherapy-induced neuropathic pain, migraine, Alzheimer's disease, and severe asthma.
Specifically, Raft has received funding to support preclinical research and development of biologic drug candidates including RFT1124, RFT1041, and RFT1081. Grants have been awarded by the National Institutes of Health, including the National Institute on Drug Abuse, National Institute of Neurological Disorders and Stroke, National Institute of Allergy and Infectious Diseases, and National Institute on Aging. The grants fall under federal drug abuse and addiction research programs, programs related to neurological disorders and stroke, allergy and infectious disease programs, and aging research programs. Deliverables provided by Raft Pharmaceuticals include conducting efficacy and toxicology studies in animal models, manufacturing drug product using cGMP-compatible processes, analyzing safety and pharmacokinetics, obtaining input from the FDA on clinical development strategies, and preparing investigational new drug applications. Through these grants, Raft Pharmaceuticals performs research and development of therapeutic candidates intended for various indications including postoperative pain, chemotherapy-induced neuropathic pain, migraine, Alzheimer’s disease, and severe asthma.
Quick answers
Is Raft Pharmaceuticals LLC registered in SAM.gov?
Yes. Raft Pharmaceuticals LLC's SAM.gov registration is active through February 12, 2027.
What is Raft Pharmaceuticals LLC's most recent federal award?
Raft Pharmaceuticals LLC's most recent federal grant award is Targeting TLR4-lipid rafts to prevent postoperative pain (R42NS132622), from National Institute of Neurological Disorders and Stroke (NIH), on September 21, 2023.
On GovTribe
See Raft Pharmaceuticals LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors